Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy

Abstract Left ventricular (LV) global peak systolic longitudinal strain (GLS) is a sensitive measurement for detecting subtle LV systolic dysfunction and a powerful prognostic predictor. However, the clinical implication of LV GLS in lymphoma patients receiving cancer therapy remains unknown. We pro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hsien-Yuan Chang, Chun-Hui Lee, Po-Lan Su, Sin-Syue Li, Ming-Yueh Chen, Ya-Ping Chen, Ya-Ting Hsu, Wei-Chuan Tsai, Ping-Yen Liu, Tsai-Yun Chen, Yen-Wen Liu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/500a2300bc3b498ba12264a2f7882f3e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:500a2300bc3b498ba12264a2f7882f3e
record_format	dspace
spelling	oai:doaj.org-article:500a2300bc3b498ba12264a2f7882f3e2021-12-02T13:26:50ZSubtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy10.1038/s41598-021-86652-x2045-2322https://doaj.org/article/500a2300bc3b498ba12264a2f7882f3e2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86652-xhttps://doaj.org/toc/2045-2322Abstract Left ventricular (LV) global peak systolic longitudinal strain (GLS) is a sensitive measurement for detecting subtle LV systolic dysfunction and a powerful prognostic predictor. However, the clinical implication of LV GLS in lymphoma patients receiving cancer therapy remains unknown. We prospectively enrolled 74 lymphoma patients (57.9 ± 17.0 years old, 57% male). We performed echocardiographic studies after the 3rd and 6th cycles and 1 year after chemotherapy and a cardiopulmonary exercise test upon completion of 3 cycles of anticancer therapy. Cancer therapy-related cardiac dysfunction (CTRCD) was defined as a ≥ 15% relative reduction in GLS value from baseline. The primary outcome was a composite of all-cause mortality and heart failure events. Thirty-six patients (49%) had CTRCD (LV GLS: baseline vs. after 3rd cycle of therapy: 20.1 ± 2.6 vs. 17.5 ± 2.3%, p < 0.001). CTRCD was detected after the 3rd cycle of anticancer therapy. CTRCD patients had impaired exercise capacity (minute oxygen consumption/kg, CTRCD vs. CTRCD (-): 13.9 ± 3.1 vs. 17.0 ± 3.9 ml/kg/min, p = 0.02). More primary outcome events occurred in the CTRCD group (hazard ratio 3.21; 95% confidence interval 1.04–9.97; p = 0.03). LV GLS could detect subtle but clinically significant cardiac dysfunction in lymphoma patients in the early stage of anticancer therapy. CTRCD may be associated with not only a reduced exercise capacity but also a worse prognosis.Hsien-Yuan ChangChun-Hui LeePo-Lan SuSin-Syue LiMing-Yueh ChenYa-Ping ChenYa-Ting HsuWei-Chuan TsaiPing-Yen LiuTsai-Yun ChenYen-Wen LiuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hsien-Yuan Chang Chun-Hui Lee Po-Lan Su Sin-Syue Li Ming-Yueh Chen Ya-Ping Chen Ya-Ting Hsu Wei-Chuan Tsai Ping-Yen Liu Tsai-Yun Chen Yen-Wen Liu Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
description	Abstract Left ventricular (LV) global peak systolic longitudinal strain (GLS) is a sensitive measurement for detecting subtle LV systolic dysfunction and a powerful prognostic predictor. However, the clinical implication of LV GLS in lymphoma patients receiving cancer therapy remains unknown. We prospectively enrolled 74 lymphoma patients (57.9 ± 17.0 years old, 57% male). We performed echocardiographic studies after the 3rd and 6th cycles and 1 year after chemotherapy and a cardiopulmonary exercise test upon completion of 3 cycles of anticancer therapy. Cancer therapy-related cardiac dysfunction (CTRCD) was defined as a ≥ 15% relative reduction in GLS value from baseline. The primary outcome was a composite of all-cause mortality and heart failure events. Thirty-six patients (49%) had CTRCD (LV GLS: baseline vs. after 3rd cycle of therapy: 20.1 ± 2.6 vs. 17.5 ± 2.3%, p < 0.001). CTRCD was detected after the 3rd cycle of anticancer therapy. CTRCD patients had impaired exercise capacity (minute oxygen consumption/kg, CTRCD vs. CTRCD (-): 13.9 ± 3.1 vs. 17.0 ± 3.9 ml/kg/min, p = 0.02). More primary outcome events occurred in the CTRCD group (hazard ratio 3.21; 95% confidence interval 1.04–9.97; p = 0.03). LV GLS could detect subtle but clinically significant cardiac dysfunction in lymphoma patients in the early stage of anticancer therapy. CTRCD may be associated with not only a reduced exercise capacity but also a worse prognosis.
format	article
author	Hsien-Yuan Chang Chun-Hui Lee Po-Lan Su Sin-Syue Li Ming-Yueh Chen Ya-Ping Chen Ya-Ting Hsu Wei-Chuan Tsai Ping-Yen Liu Tsai-Yun Chen Yen-Wen Liu
author_facet	Hsien-Yuan Chang Chun-Hui Lee Po-Lan Su Sin-Syue Li Ming-Yueh Chen Ya-Ping Chen Ya-Ting Hsu Wei-Chuan Tsai Ping-Yen Liu Tsai-Yun Chen Yen-Wen Liu
author_sort	Hsien-Yuan Chang
title	Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
title_short	Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
title_full	Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
title_fullStr	Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
title_full_unstemmed	Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
title_sort	subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/500a2300bc3b498ba12264a2f7882f3e
work_keys_str_mv	AT hsienyuanchang subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT chunhuilee subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT polansu subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT sinsyueli subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT mingyuehchen subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT yapingchen subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT yatinghsu subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT weichuantsai subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT pingyenliu subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT tsaiyunchen subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy AT yenwenliu subtlecardiacdysfunctioninlymphomapatientsreceivinglowtomoderatedosechemotherapy
_version_	1718393028995973120

Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy

Ejemplares similares